Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9904 |
Bevacizumab
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Bevacizumab 是一种人源化单克隆抗体,能以高亲和力与所有血管内皮生长因子-A 异构体特异性结合。 | |||
T36314 |
Wortmannin-Rapamycin Conjugate
|
||
Phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) act synergistically in promoting cancer. Wortmannin is a potent inhibitor of PI3K enzymes, while rapamycin blocks mTOR Complex 1 TORC1. Wortmannin-rapamycin conjugate consists of analogs of 17-hydroxy wortmannin and rapamycin conjugated via a prodrug linker. Hydrolysis of the prodrug linker in vivo releases the inhibitors. The wortmannin-rapamycin conjugate inhibits the growth of HT-29 colon tumors and A498 renal tumors in... |